Nephros (NEPH) Equity Average (2011 - 2026)

Nephros' Equity Average history runs 16 years deep, the most recent figure standing at $10.5 million for Q1 2026.

• In Q1 2026, Equity Average rose 16.93% year-over-year to $10.5 million; the TTM figure through Mar 2026 stood at $10.5 million (up 16.93% YoY), while the FY2025 annual figure was $9.4 million, up 10.88% from the prior year.
• Equity Average was $10.5 million for Q1 2026 at Nephros, up from $10.1 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $14.1 million in Q1 2022 to a low of $8.0 million in Q3 2024.
• Historically, Equity Average has averaged $9.6 million across 5 years, with a median of $8.9 million in 2025.
• The sharpest annual moves came in 2022 and 2025: Equity Average slumped 38.62% in 2022, then rose 21.77% in 2025.
• A 5-year view of Equity Average shows it stood at $9.2 million in 2022, then decreased by 8.03% to $8.5 million in 2023, then declined by 1.3% to $8.4 million in 2024, then rose by 20.58% to $10.1 million in 2025, then advanced by 3.44% to $10.5 million in 2026.
• The last three Equity Average figures came in at $10.5 million (Q1 2026), $10.1 million (Q4 2025), and $9.8 million (Q3 2025), per Business Quant data.